Skip to main content
Clinical Trials/NCT03397849
NCT03397849
Completed
Not Applicable

Lifestyle Intervention Using Mobile Technology in Patients With High Cardiovascular Risk

Ministry of Health, Turkey1 site in 1 country320 target enrollmentFebruary 1, 2018

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Primary Prevention
Sponsor
Ministry of Health, Turkey
Enrollment
320
Locations
1
Primary Endpoint
Atherosclerotic cardiovascular disease (ASCVD) risk score of individual patients at 12 months that is adjusted to baseline ASCVD risk score.
Status
Completed
Last Updated
6 years ago

Overview

Brief Summary

In the present study, investigators aim to compare intervention using mobile technology (IMT) plus usual care with only usual care in patients with a high risk for cardiovascular diseases (CVD). Investigators hypothesize that IMT plus usual care reduces the CVD risk and improves the secondary outcomes in this population through 12 months of follow-up period. Patients presented to the outpatient clinics in a tertiary hospital (Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Research and Training Hospital, Istanbul, Turkey) who were considered to be eligible according to inclusion and exclusion criteria will be enrolled to the study. The eligibility criteria is; Patients between 20 to 79 years old who are in high risk for CVD (10 years ASCVD risk ≥ 7.5%). Patients with prior CVD events (myocardial infarction, percutaneous coronary intervention, coronary artery by-pass grafting operation, stroke and peripheral artery disease), pregnancy, communication problems, severe neuropsychiatric problems and chronic kidney disease are excluded from the study. In addition, patients that are unable to use smartphone phone are also excluded.

Registry
clinicaltrials.gov
Start Date
February 1, 2018
End Date
March 1, 2020
Last Updated
6 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Ministry of Health, Turkey
Responsible Party
Principal Investigator
Principal Investigator

Ahmet İlker Tekkeşin

Principal investigator

Ministry of Health, Turkey

Eligibility Criteria

Inclusion Criteria

  • Presence of high risk for cardiovascular diseases (ASCVD risk score \> 7.5%).

Exclusion Criteria

  • Patients with prior cardiovascular events including myocardial infarction, percutaneous coronary intervention, coronary artery by-pass grafting operation, stroke and peripheral artery disease.
  • Pregnancy
  • Patients with communication problems or severe neuropsychiatric problems
  • Patients with chronic kidney disease
  • Patients who are considered for being unable to use smart phone

Outcomes

Primary Outcomes

Atherosclerotic cardiovascular disease (ASCVD) risk score of individual patients at 12 months that is adjusted to baseline ASCVD risk score.

Time Frame: 12 months

Patients with ASCVD risk score of \>7.5 % are considered to have a high risk for 10-year atherosclerotic cardiovascular diseases.

Secondary Outcomes

  • Improvement in quality of life(12 months)
  • HbA1c (%) level at 12 months that is adjusted to baseline level(12 months)
  • Plasma fasting lipid levels (total cholesterol, low density lipoprotein, high density lipoprotein and trigliserid) (mg/dL) at 12 months that are adjusted to baseline levels(12 months)
  • Carotis intima-media thickness (mm) value at 12 months that is adjusted to baseline value(12 months)
  • Smoke abstinence(12 months)
  • Improvement in high sensitive C reactive protein levels (hs-CRP) (mg/L) (hs-CRP value at 12 months that is adjusted to baseline value)(12 months)
  • Peak oxygen consumption value at 12 months that is adjusted to baseline value(12 months)
  • Major adverse cardiovascular events(12 months)
  • Systolic and diastolic blood pressure values (mmHg) at 12 months that are adjusted to baseline values(12 months)
  • Body mass index (BMI) (kg/m^2) level at 12 months that is adjusted to baseline level(12 months)

Study Sites (1)

Loading locations...

Similar Trials